Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons
- PMID: 10768293
- DOI: 10.1111/j.1528-1157.2000.tb02164.x
Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons
Abstract
Purpose: This study was undertaken to evaluate the effects of topiramate (TPM) on excitatory amino acid-evoked currents.
Methods: Kainate and N-methyl-D-aspartate (NMDA) were applied to cultured rat hippocampal neurons by using a concentration-clamp apparatus to selectively activate the AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid)/kainate and NMDA receptor subtypes, respectively. The evoked membrane currents were recorded by using perforated-patch whole-cell voltage-clamp techniques.
Results: TPM partially blocked kainate-evoked currents with an early-onset reversible phase (phase I) and a late-onset phase (phase II) that occurred after a 10- to 20-min delay and did not reverse during a 2-h washout period. Application of dibutyryl cyclic adenosine monophosphate (cAMP; 2 mM) during washout after phase II block enhanced reversal, with the kainate current amplitude being restored by approximately 50%. Phase II but not phase I block was prevented by prior application of okadaic acid (1 microM), a broad-spectrum phosphatase inhibitor, suggesting that phase II block may be mediated through interactions with intracellular intermediaries that alter the phosphorylation state of kainate-activated channels. Topiramate at 100 microM blocked kainate-evoked currents by 90% during phase II, but had no effect on NMDA-evoked currents. The median inhibitory concentration (IC50) values for phase I and II block of kainate currents were 1.6 and 4.8 microM, respectively, which are within the range of free serum levels of TPM in patients.
Conclusions: The specific blockade of the kainate-induced excitatory conductance is consistent with the ability of TPM to reduce neuronal excitability and could contribute to the anticonvulsant efficacy of this drug.
Similar articles
-
Pharmacological characterization of a GluR6 kainate receptor in cultured hippocampal neurons.Eur J Pharmacol. 1999 Aug 13;378(3):331-7. doi: 10.1016/s0014-2999(99)00478-1. Eur J Pharmacol. 1999. PMID: 10493110
-
Effects of competitive NMDA receptor antagonists on excitatory amino acid-evoked currents in mouse spinal cord neurones.Fundam Clin Pharmacol. 1999;13(1):67-74. doi: 10.1111/j.1472-8206.1999.tb00322.x. Fundam Clin Pharmacol. 1999. PMID: 10027090
-
Topiramate blocks kainate-evoked cobalt influx into cultured neurons.Epilepsia. 2000;41(S1):45-7. doi: 10.1111/j.1528-1157.2000.tb02171.x. Epilepsia. 2000. PMID: 10768300
-
An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action.Epilepsia. 2000;41(S1):3-9. Epilepsia. 2000. PMID: 10768292 Review.
-
Targeting AMPA and kainate receptors in neurological disease: therapies on the horizon?Neuropsychopharmacology. 2009 Jan;34(1):249-50. doi: 10.1038/npp.2008.158. Neuropsychopharmacology. 2009. PMID: 19079074 Free PMC article. Review. No abstract available.
Cited by
-
Advances in topiramate as prophylactic treatment for migraine.Brain Behav. 2021 Oct;11(10):e2290. doi: 10.1002/brb3.2290. Epub 2021 Sep 2. Brain Behav. 2021. PMID: 34472696 Free PMC article. Review.
-
Topiramate-antagonism of L-glutamate-induced paroxysms in planarians.Eur J Pharmacol. 2010 Dec 15;649(1-3):150-3. doi: 10.1016/j.ejphar.2010.09.021. Epub 2010 Sep 19. Eur J Pharmacol. 2010. PMID: 20863783 Free PMC article.
-
Effectiveness and safety of pharmacological prophylaxis for chronic migraine: a systematic review and network meta-analysis.J Neurol. 2024 Sep;271(9):5762-5777. doi: 10.1007/s00415-024-12512-z. Epub 2024 Jun 23. J Neurol. 2024. PMID: 38910144
-
Interactions among Lacosamide and Second-Generation Antiepileptic Drugs in the Tonic-Clonic Seizure Model in Mice.Int J Mol Sci. 2021 May 24;22(11):5537. doi: 10.3390/ijms22115537. Int J Mol Sci. 2021. PMID: 34073930 Free PMC article.
-
Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.CNS Drugs. 2005;19(10):873-96. doi: 10.2165/00023210-200519100-00005. CNS Drugs. 2005. PMID: 16185095 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources